N@N

Positron Receives Highest Mark of Compliance from Nuclear Regulatory Commission

^{Published on 2010-12-06 15:05:15 - Market Wire}
 

INDIANAPOLIS--([ BUSINESS WIRE ])--Positron Corporation (OTCBB:POSC), a leading molecular imaging company specializing in the field of nuclear cardiology, today announced it had achieved the highest mark of compliance in a recent inspection by the Nuclear Regulatory Commission (NRC).

"Our internal processes and controls are always driven to ensure we adhere to the highest degree of compliance, this is further evidence of Positrona™s overall commitment to excellence"

The NRC performed a safety inspection of Positrona™s Indianapolis facility this past Thursday and issued a compliance report (FORM 591M Part 1) with its findings. The report indicated Positron achieved the highest possible compliance notice (with no violations) available from this Federal regulatory body, which monitors radioactive material (RAM) license holders.

aThe NRC has a strong reputation for rigorousness and insistence on its standards of procedural verification, training and documentation. A RAM license is key to our radiopharmaceutical programs in order to conduct critical research & development and manufacturing, now and in the future. More immediately, we will be conducting validation testing prior to shipment of commercial products from our Nuclear Cardio-Assista" line.a

aOur internal processes and controls are always driven to ensure we adhere to the highest degree of compliance, this is further evidence of Positrona™s overall commitment to excellence,a stated Positron CEO Patrick G. Rooney.

The NRC periodically inspects the procedures and documentation of RAM license holders, such as imaging centers, nuclear pharmacies and producers of radioactive products, to ensure safe and proper handling of radioactive material. Inspections are an examination of the activities conducted under a license issued by the NRC, an independent Federal agency. A RAM license is required to produce and handle radioactive pharmaceuticals. Positron received its RAM license from the NRC in December 2009 to support its imaging device and pharmaceutical programs.

About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius®, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assista", a radiopharmaceutical injection shield. More information about Positron is available at [ www.positron.com ].

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

For further information please contact Positron Corporation at (317)576-0183.